Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History GANX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics GANX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Gain Therapeutics Inc

GANX
Current price
1.62 USD +0.05 USD (+3.18%)
Last closed 1.70 USD
ISIN US36269B1052
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 53 003 712 USD
Yield for 12 month +27.56 %
1Y
3Y
5Y
10Y
15Y
GANX
21.11.2021 - 28.11.2021

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland. Address: 4800 Montgomery Lane, Bethesda, MD, United States, 20814

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

8.00 USD

P/E Ratio

Dividend Yield

Financials GANX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures GANX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

+55 180 USD

Current Quarter

Last Quarter

Current Year

-84 071 USD

Last Year

-25 202 USD

Current Quarter

Last Quarter

-21 307 USD
EBITDA -20 314 820 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -97.10 %
PEG Ratio
Return On Equity TTM -290.22 %
Wall Street Target Price 8.00 USD
Revenue TTM
Book Value 0.20 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM -10 402 438 USD
Earnings per share -0.83 USD
Diluted Eps TTM -0.83 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation GANX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 138.33
Price Sales TTM 255.50
Enterprise Value EBITDA -1.55
Price Book MRQ 9.17

Technical Indicators GANX

For 52 Weeks

0.89 USD 3.19 USD
50 Day MA 1.85 USD
Shares Short Prior Month 232 307
200 Day MA 2.00 USD
Short Ratio 0.98
Shares Short 252 124
Short Percent 0.81 %